Citius Pharmaceuticals

Historical price data

Citius Pharmaceuticals is a late-stage biopharma company with a mission to develop and commercialize first-in-class critical care products. Its key achievement is the FDA approval and commercialization of LYMPHIR™ for cutaneous T-cell lymphoma, marking its transition to a commercial-stage entity. The company's strategy is built on a diversified pipeline targeting high-need areas like catheter-related infections and adjunct cancer care, with a core focus on accelerating promising therapies through late-stage development. Financially, it operates as a micro-cap public company, navigating the capital-intensive path of drug development while managing a lean operational structure.

Citius employs a targeted asset development and in-licensing strategy rather than a proprietary discovery platform, focusing on accelerating late-stage or approved candidates through clinical development and regulatory approval for critical care and oncology indications.

Citius competes in niche, high-need segments: LYMPHIR™ faces competition in the relapsed CTCL market, while Mino-Lok®'s main competitor is the standard of care (catheter removal), offering a first-mover advantage if successful. The company's strategy avoids direct competition with large pharma in primary care but requires demonstrating superior clinical value to change established medical practices.